HCW 9302
Alternative Names: HCW-9302Latest Information Update: 04 Apr 2024
At a glance
- Originator HCW Biologics
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Inflammasome modulators; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- Preclinical Alopecia areata; Autoimmune disorders
Most Recent Events
- 01 Apr 2024 HCW Biologics intends to file an IND application for Autoimmune disorders in the first half of 2024 (HCW Biologics pipeline, January 2024)
- 03 Apr 2023 HCW Biologics plans a clinical trial for Atherosclerosis
- 03 Aug 2022 HCW Biologics has patent protection for TOBI™ platform technology in USA